Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-09-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事关于公司第七届董事会第二十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's third restricted stock incentive plan, including confirmation of the grant date and compliance with relevant regulations. It is a formal statement related to board meeting decisions on stock incentives, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement or a certification letter but a board-related opinion on management decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management regarding company governance and incentives.
2022-09-19 Chinese
第三期限制性股票激励计划首次授予部分激励对象名单（授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a detailed list of individuals receiving restricted stock awards under a stock incentive plan, including their positions and the number of shares granted. It focuses on the allocation of restricted stock to executives and employees, which is typical of disclosures related to stock incentive plans or equity compensation. There is no indication of financial statements, audit opinions, earnings data, or meeting materials. The content is about the granting of restricted stock incentives, which is a capital-related announcement but not a general capital raising or financing update. It is not a report or a meeting announcement but a specific disclosure about stock incentives. This type of document fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance of restricted shares as part of an incentive plan.
2022-09-19 Chinese
关于公司第三期限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Director's Dealing Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a restricted stock incentive plan. It details the investigation of insider trading by insiders before the public disclosure of the plan, referencing regulatory guidelines and internal procedures. The document does not contain financial statements or earnings data, nor is it an announcement of voting results or a general regulatory filing. It specifically reports on insider transactions related to a stock incentive plan, which aligns with the category of Director's Dealing (DIRS), as it involves reporting on insider share transactions by company directors and executives.
2022-09-19 Chinese
关于第七届监事会第二十一次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the supervisory board (监事会) of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the approval of the initial grant of restricted stock under the company's third restricted stock incentive plan. It details the meeting date, voting results, and the specifics of the stock grant (number of shares, price, and recipients). This is a corporate governance-related announcement about stock incentives to employees or management, not a full financial report or earnings release. It is not a report itself but an announcement of a board decision related to share-based incentives. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement about internal corporate matters and stock incentive approvals, without detailed financial statements or broader management discussion.
2022-09-19 Chinese
关于第七届董事会第二十四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of Anhui Anke Biotechnology (Group) Co., Ltd. It details decisions about adjustments to a restricted stock incentive plan and the initial grant of restricted stock to incentive recipients. The document includes voting results and mentions the board meeting date and participants. It does not contain financial statements, audit opinions, or detailed financial data. It is not a full annual or interim report, nor is it a regulatory filing or certification. The content is focused on board decisions and management matters related to stock incentives, which fits the category of Board/Management Information (MANG). The document length is short (1223 characters), and it is not merely an announcement of a report but a substantive announcement of board resolutions.
2022-09-19 Chinese
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2022 second extraordinary general meeting of shareholders of Anhui Anke Biological Engineering (Group) Co., Ltd. It details the meeting date, attendance, voting results on several proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders during the meeting. There is no presentation material, financial statements, or detailed management discussion. The document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4656 characters, which is sufficient for a detailed voting result announcement rather than a brief notice or a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2022-09-13 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.